Floatz logo

Tc-D101 Car-T

CAR-T Cell Therapy

TCRCure Biopharma Ltd.Cell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the CAR-T Cell Therapy cohort.

Asset / SponsorPhaseRating
Anakinra
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1/2CC
A-Car028
First Affiliated Hospital of Zhejiang University
Phase 1CC
Chimeric Antigen Receptor Modified T Cells Infusion
Second Affiliated Hospital of Guangzhou Medical University
Phase 1CC
Fludarabine
TCRCure Biopharma Ltd.
Early Phase 1C
Cyclophosphamide
TCRCure Biopharma Ltd.
Early Phase 1C
Ari-0001
The Affiliated Hospital of Xuzhou Medical University
N/AD
Axicabtagene Ciloleucel
Ruijin Hospital
N/AD

Same molecule, other indications

Tc-D101 Car-T is also rated in:

small cell lung carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →